This page is part of the Respiratory Virus Hospitalization Surveillance Network (RESP-NET) Content Implementation Guide (v1.0.0: STU1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Official URL: http://hl7.org/fhir/us/resp-net/ValueSet/resp-net-labtest-covid-codes | Version: 1.0.0 | |||
Standards status: Informative | Computable Name: RESPNetCovidCodes | |||
Other Identifiers: OID:2.16.840.1.113883.4.642.40.52.48.2 | ||||
Usage:Reporting: Triggering, Priority: Routine |
||||
Copyright/Legal: This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Current Procedural Terminology (CPT) is copyright 2020 American Medical Association. All rights reserved |
List of Covid test codes
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
version: 1; Last updated: 2024-08-19 22:06:32+0000
Profile: US Public Health Triggering ValueSet
This value set includes codes based on the following rules:
http://loinc.org
Code | Display |
102048-6 | SARS coronavirus 2 & Respiratory syncytial virus Ag |
95941-1 | Influenza virus A & Influenza virus B & SARS coronavirus 2 & Respiratory syncytial virus RNA panel |
100861-4 | Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
100858-0 | Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide |
100862-2 | Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
100859-8 | Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide |
100863-0 | Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
100860-6 | Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide |
95942-9 | Influenza virus A & Influenza virus B & SARS coronavirus+SARS coronavirus 2 Ag panel |
97099-6 | Influenza virus A & Influenza virus B & SARS coronavirus 2 Ag panel |
95941-1 | Influenza virus A & Influenza virus B & SARS coronavirus 2 & Respiratory syncytial virus RNA panel |
95380-2 | Influenza virus A & Influenza virus B & SARS coronavirus 2 & SARS-related coronavirus RNA panel |
95423-0 | Influenza virus A & Influenza virus B & SARS coronavirus 2 identified |
95422-2 | Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel |
100345-8 | Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel |
98733-9 | Percent neutralization by SARS coronavirus 2 spike protein RBD Ab.neut |
99771-8 | SARS coronavirus 2 spike & nucleocapsid protein stimulated gamma interferon panel |
98846-9 | SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells^^corrected for background |
98847-7 | SARS coronavirus 2 stimulated gamma interferon release by lymphocytes^^corrected for background |
99774-2 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count^^corrected for background |
99773-4 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count^^corrected for background |
95209-3 | SARS coronavirus+SARS coronavirus 2 Ag |
94763-0 | SARS coronavirus 2 |
94661-6 | SARS coronavirus 2 Ab |
95825-6 | SARS coronavirus 2 Ab |
98069-8 | SARS coronavirus 2 Ab |
94762-2 | SARS coronavirus 2 Ab |
95542-7 | SARS coronavirus 2 Ab |
94769-7 | SARS coronavirus 2 Ab |
96118-5 | SARS coronavirus 2 Ab panel |
94504-8 | SARS coronavirus 2 Ab panel |
94503-0 | SARS coronavirus 2 Ab panel |
94558-4 | SARS coronavirus 2 Ag |
96119-3 | SARS coronavirus 2 Ag |
97097-0 | SARS coronavirus 2 Ag |
96094-8 | SARS coronavirus 2 & SARS-related coronavirus RNA panel |
98080-5 | SARS coronavirus 2 & SARS-related coronavirus RNA panel |
96896-6 | SARS coronavirus 2 clade |
96764-6 | SARS coronavirus 2 E gene |
96763-8 | SARS coronavirus 2 E gene |
94562-6 | SARS coronavirus 2 Ab.IgA |
94768-9 | SARS coronavirus 2 Ab.IgA |
95427-1 | SARS coronavirus 2 Ab.IgA |
94720-0 | SARS coronavirus 2 Ab.IgA |
95125-1 | SARS coronavirus 2 Ab.IgA+IgM |
96742-2 | SARS coronavirus 2 Ab.IgG |
94761-4 | SARS coronavirus 2 Ab.IgG |
94563-4 | SARS coronavirus 2 Ab.IgG |
94507-1 | SARS coronavirus 2 Ab.IgG |
95429-7 | SARS coronavirus 2 Ab.IgG |
94505-5 | SARS coronavirus 2 Ab.IgG |
94547-7 | SARS coronavirus 2 Ab.IgG+IgM |
95416-4 | SARS coronavirus 2 Ab.IgM |
94564-2 | SARS coronavirus 2 Ab.IgM |
94508-9 | SARS coronavirus 2 Ab.IgM |
95428-9 | SARS coronavirus 2 Ab.IgM |
94506-3 | SARS coronavirus 2 Ab.IgM |
96895-8 | SARS coronavirus 2 lineage |
100157-7 | SARS coronavirus 2 lineage |
96957-6 | SARS coronavirus 2 M gene |
103557-5 | SARS coronavirus 2 Mpro gene mutation detected |
95521-1 | SARS coronavirus 2 N gene |
96898-2 | SARS coronavirus 2 N gene |
94510-5 | SARS coronavirus 2 N gene |
94311-8 | SARS coronavirus 2 N gene |
94312-6 | SARS coronavirus 2 N gene |
95522-9 | SARS coronavirus 2 N gene |
94760-6 | SARS coronavirus 2 N gene |
96986-5 | SARS coronavirus 2 N gene |
95409-9 | SARS coronavirus 2 N gene |
94533-7 | SARS coronavirus 2 N gene |
94756-4 | SARS coronavirus 2 N gene |
94757-2 | SARS coronavirus 2 N gene |
95425-5 | SARS coronavirus 2 N gene |
96448-6 | SARS coronavirus 2 N gene |
96958-4 | SARS coronavirus 2 N gene |
94766-3 | SARS coronavirus 2 N gene |
94316-7 | SARS coronavirus 2 N gene |
94307-6 | SARS coronavirus 2 N gene |
94308-4 | SARS coronavirus 2 N gene |
99596-9 | SARS coronavirus 2 nucleocapsid protein Ab.IgG |
95411-5 | SARS coronavirus 2 Ab.neut |
95410-7 | SARS coronavirus 2 Ab.neut |
97098-8 | SARS coronavirus 2 Nsp2 gene |
98132-4 | SARS coronavirus 2 ORF1a region |
98494-8 | SARS coronavirus 2 ORF1a region |
96899-0 | SARS coronavirus 2 ORF1ab region |
94644-2 | SARS coronavirus 2 ORF1ab region |
94511-3 | SARS coronavirus 2 ORF1ab region |
94559-2 | SARS coronavirus 2 ORF1ab region |
95824-9 | SARS coronavirus 2 ORF1ab region |
94639-2 | SARS coronavirus 2 ORF1ab region |
97104-4 | SARS coronavirus 2 ORF1ab region |
98131-6 | SARS coronavirus 2 ORF1b region |
98493-0 | SARS coronavirus 2 ORF1b region |
94646-7 | SARS coronavirus 2 RdRp gene |
94645-9 | SARS coronavirus 2 RdRp gene |
96120-1 | SARS coronavirus 2 RdRp gene |
94534-5 | SARS coronavirus 2 RdRp gene |
96091-4 | SARS coronavirus 2 RdRp gene |
94314-2 | SARS coronavirus 2 RdRp gene |
96123-5 | SARS coronavirus 2 RdRp gene |
99314-7 | SARS coronavirus 2 RdRp gene mutation detected |
94745-7 | SARS coronavirus 2 RNA |
94746-5 | SARS coronavirus 2 RNA |
94819-0 | SARS coronavirus 2 RNA |
94565-9 | SARS coronavirus 2 RNA |
94759-8 | SARS coronavirus 2 RNA |
95406-5 | SARS coronavirus 2 RNA |
96797-6 | SARS coronavirus 2 RNA |
95608-6 | SARS coronavirus 2 RNA |
94500-6 | SARS coronavirus 2 RNA |
95424-8 | SARS coronavirus 2 RNA |
94845-5 | SARS coronavirus 2 RNA |
94822-4 | SARS coronavirus 2 RNA |
94660-8 | SARS coronavirus 2 RNA |
94309-2 | SARS coronavirus 2 RNA |
96829-7 | SARS coronavirus 2 RNA |
96897-4 | SARS coronavirus 2 RNA panel |
94531-1 | SARS coronavirus 2 RNA panel |
95826-4 | SARS coronavirus 2 RNA panel |
94306-8 | SARS coronavirus 2 RNA panel |
96900-6 | SARS coronavirus 2 S gene |
94642-6 | SARS coronavirus 2 S gene |
94643-4 | SARS coronavirus 2 S gene |
94640-0 | SARS coronavirus 2 S gene |
95609-4 | SARS coronavirus 2 S gene |
96765-3 | SARS coronavirus 2 S gene |
94767-1 | SARS coronavirus 2 S gene |
94641-8 | SARS coronavirus 2 S gene |
96752-1 | SARS coronavirus 2 S gene mutation |
96751-3 | SARS coronavirus 2 S gene mutation detected |
99597-7 | SARS coronavirus 2 spike protein Ab.IgG |
96603-6 | SARS coronavirus 2 spike protein RBD Ab.neut |
98732-1 | SARS coronavirus 2 spike protein RBD Ab.neut |
98734-7 | SARS coronavirus 2 spike protein RBD Ab.neut |
96894-1 | SARS coronavirus 2 sequencing & identification panel |
95970-0 | SARS coronavirus 2 specific TCRB gene rearrangements |
100156-9 | SARS coronavirus 2 variant |
96741-4 | SARS coronavirus 2 variant |
96755-4 | SARS coronavirus 2 variant interpretation |
94764-8 | SARS coronavirus 2 whole genome |
99772-6 | SARS coronavirus 2 stimulated gamma interferon |
95971-8 | SARS coronavirus 2 stimulated gamma interferon |
95974-2 | SARS coronavirus 2 stimulated gamma interferon panel |
95972-6 | SARS coronavirus 2 stimulated gamma interferon release by T-cells^^corrected for background |
95973-4 | SARS coronavirus 2 stimulated gamma interferon release by T-cells |
94509-7 | SARS-related coronavirus E gene |
96121-9 | SARS-related coronavirus E gene |
94758-0 | SARS-related coronavirus E gene |
95823-1 | SARS-related coronavirus E gene |
94765-5 | SARS-related coronavirus E gene |
94315-9 | SARS-related coronavirus E gene |
96122-7 | SARS-related coronavirus E gene |
94313-4 | SARS-related coronavirus N gene |
94310-0 | SARS-related coronavirus N gene |
94502-2 | SARS-related coronavirus RNA |
94647-5 | SARS-related coronavirus RNA |
94532-9 | SARS-related coronavirus+MERS coronavirus RNA |
100342-5 | Volatile Organic Compounds associated with SARS-CoV-2 infection |
100972-9 | Influenza virus A and Influenza virus B and SARS coronavirus 2 RNA panel - Nose by NAA with non-probe detection |
http://www.ama-assn.org/go/cpt
Code | Display |
87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
87631 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when perfor |
87632 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when perfor |
87633 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when perfor |
87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique |
87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
0241U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen |
87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique |
87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
86328 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
86408 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen |
86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer |
86413 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative |
87811 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
0224U | Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed |
0226U | Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum |
0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen rep |
0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen rep |
0225U | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for |
87913 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s) |
0240U | Detection of SARS-CoV-2, Influenza A and Influenza B |
87426 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute resp |
87428 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute resp |
86318 | Immunoassay for infectious agent antibody(ies) and to be a parent to 86328 |
87252 | Viral Culture, General; Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect |
Expansion from tx.fhir.org based on:
This value set has 187 codes in it. In order to keep the publication size manageable, only a selection (183 codes) of the whole set of codes is shown.
Code | System | Display (en-US) |
102048-6 | http://loinc.org | SARS coronavirus 2 and Respiratory syncytial virus Ag [Presence] in Nasopharynx by Immunofluorescence |
95941-1 | http://loinc.org | Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection |
100861-4 | http://loinc.org | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
100858-0 | http://loinc.org | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide |
100862-2 | http://loinc.org | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
100859-8 | http://loinc.org | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide |
100863-0 | http://loinc.org | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
100860-6 | http://loinc.org | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide |
95942-9 | http://loinc.org | Influenza virus A and B and SARS-CoV+SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay |
97099-6 | http://loinc.org | Influenza virus A and B and SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay |
95380-2 | http://loinc.org | Influenza virus A and B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory system specimen by NAA with probe detection |
95423-0 | http://loinc.org | Influenza virus A and B and SARS-CoV-2 (COVID-19) identified in Respiratory system specimen by NAA with probe detection |
95422-2 | http://loinc.org | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection |
100345-8 | http://loinc.org | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection |
98733-9 | http://loinc.org | Percent neutralization by SARS coronavirus 2 spike protein RBD neutralizing antibody in Serum or Plasma by Immunoassay |
99771-8 | http://loinc.org | SARS coronavirus 2 spike and nucleocapsid protein stimulated gamma interferon panel - Blood |
98846-9 | http://loinc.org | SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells [Units/volume] corrected for background in Blood by Immunoassay |
98847-7 | http://loinc.org | SARS coronavirus 2 stimulated gamma interferon release by lymphocytes [Units/volume] corrected for background in Blood by Immunoassay |
99774-2 | http://loinc.org | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count [#] corrected for background in Blood |
99773-4 | http://loinc.org | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count [#] corrected for background in Blood |
95209-3 | http://loinc.org | SARS-CoV+SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory system specimen by Rapid immunoassay |
94763-0 | http://loinc.org | SARS-CoV-2 (COVID-19) [Presence] in Specimen by Organism specific culture |
94661-6 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab [Interpretation] in Serum or Plasma |
95825-6 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay |
98069-8 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab [Presence] in Saliva (oral fluid) by Rapid immunoassay |
94762-2 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab [Presence] in Serum or Plasma by Immunoassay |
95542-7 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
94769-7 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab [Units/volume] in Serum or Plasma by Immunoassay |
96118-5 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab panel - DBS by Immunoassay |
94504-8 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab panel - Serum or Plasma by Immunoassay |
94503-0 | http://loinc.org | SARS-CoV-2 (COVID-19) Ab panel - Serum, Plasma or Blood by Rapid immunoassay |
94558-4 | http://loinc.org | SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory system specimen by Rapid immunoassay |
96119-3 | http://loinc.org | SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay |
97097-0 | http://loinc.org | SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay |
96094-8 | http://loinc.org | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory system specimen by NAA with probe detection |
98080-5 | http://loinc.org | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Saliva (oral fluid) by NAA with probe detection |
96896-6 | http://loinc.org | SARS-CoV-2 (COVID-19) clade [Type] in Specimen by Molecular genetics method |
96764-6 | http://loinc.org | SARS-CoV-2 (COVID-19) E gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection |
96763-8 | http://loinc.org | SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory system specimen by NAA with probe detection |
94562-6 | http://loinc.org | SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum or Plasma by Immunoassay |
94768-9 | http://loinc.org | SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
95427-1 | http://loinc.org | SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence |
94720-0 | http://loinc.org | SARS-CoV-2 (COVID-19) IgA Ab [Units/volume] in Serum or Plasma by Immunoassay |
95125-1 | http://loinc.org | SARS-CoV-2 (COVID-19) IgA+IgM [Presence] in Serum or Plasma by Immunoassay |
96742-2 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay |
94761-4 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in DBS by Immunoassay |
94563-4 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum or Plasma by Immunoassay |
94507-1 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
95429-7 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence |
94505-5 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay |
94547-7 | http://loinc.org | SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay |
95416-4 | http://loinc.org | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in DBS by Immunoassay |
94564-2 | http://loinc.org | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum or Plasma by Immunoassay |
94508-9 | http://loinc.org | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
95428-9 | http://loinc.org | SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence |
94506-3 | http://loinc.org | SARS-CoV-2 (COVID-19) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay |
96895-8 | http://loinc.org | SARS-CoV-2 (COVID-19) lineage [Identifier] in Specimen by Molecular genetics method |
100157-7 | http://loinc.org | SARS-CoV-2 (COVID-19) lineage [Type] in Specimen by Sequencing |
96957-6 | http://loinc.org | SARS-CoV-2 (COVID-19) M gene [Presence] in Upper respiratory specimen by NAA with probe detection |
103557-5 | http://loinc.org | SARS-CoV-2 (COVID-19) Mpro gene mutation detected [Identifier] in Specimen by Molecular genetics method Nominal |
95521-1 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory system specimen by NAA with probe detection |
96898-2 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection |
94510-5 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by NAA with probe detection |
94311-8 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 |
94312-6 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 |
95522-9 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Log #/volume] (viral load) in Respiratory system specimen by NAA with probe detection |
94760-6 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Nasopharynx by NAA with probe detection |
96986-5 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with non-probe detection |
95409-9 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection |
94533-7 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by NAA with probe detection |
94756-4 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by Nucleic acid amplification using CDC primer-probe set N1 |
94757-2 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by Nucleic acid amplification using CDC primer-probe set N2 |
95425-5 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
96448-6 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N1 |
96958-4 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N2 |
94766-3 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Serum or Plasma by NAA with probe detection |
94316-7 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by NAA with probe detection |
94307-6 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 |
94308-4 | http://loinc.org | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 |
99596-9 | http://loinc.org | SARS-CoV-2 (COVID-19) N protein IgG Ab [Presence] in Serum or Plasma by Immunoassay |
95411-5 | http://loinc.org | SARS-CoV-2 (COVID-19) neutralizing antibody [Presence] in Serum by pVNT |
95410-7 | http://loinc.org | SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT |
97098-8 | http://loinc.org | SARS-CoV-2 (COVID-19) Nsp2 gene [Presence] in Upper respiratory specimen by NAA with probe detection |
98132-4 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Respiratory system specimen by NAA with probe detection |
98494-8 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Saliva (oral fluid) by NAA with probe detection |
96899-0 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection |
94644-2 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection |
94511-3 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Specimen by NAA with probe detection |
94559-2 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Respiratory system specimen by NAA with probe detection |
95824-9 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection |
94639-2 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Specimen by NAA with probe detection |
97104-4 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1ab region [Units/volume] (viral load) in Upper respiratory specimen by NAA with probe detection |
98131-6 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Respiratory system specimen by NAA with probe detection |
98493-0 | http://loinc.org | SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Saliva (oral fluid) by NAA with probe detection |
94646-7 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection |
94645-9 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Specimen by NAA with probe detection |
96120-1 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Lower respiratory specimen by NAA with probe detection |
94534-5 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Respiratory system specimen by NAA with probe detection |
96091-4 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
94314-2 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection |
96123-5 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection |
99314-7 | http://loinc.org | SARS-CoV-2 (COVID-19) RdRp gene mutation detected [Identifier] in Specimen by Molecular genetics method |
94745-7 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection |
94746-5 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Specimen by NAA with probe detection |
94819-0 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection |
94565-9 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection |
94759-8 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection |
95406-5 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection |
96797-6 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Oropharyngeal wash by NAA with probe detection |
95608-6 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with non-probe detection |
94500-6 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection |
95424-8 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by Sequencing |
94845-5 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by NAA with probe detection |
94822-4 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by Sequencing |
94660-8 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Serum or Plasma by NAA with probe detection |
94309-2 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection |
96829-7 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen from Donor by NAA with probe detection |
96897-4 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA panel - Oropharyngeal wash by NAA with probe detection |
94531-1 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection |
95826-4 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection |
94306-8 | http://loinc.org | SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection |
96900-6 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection |
94642-6 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection |
94643-4 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Specimen by NAA with probe detection |
94640-0 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory system specimen by NAA with probe detection |
95609-4 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory system specimen by Sequencing |
96765-3 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
94767-1 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Presence] in Serum or Plasma by NAA with probe detection |
94641-8 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene [Presence] in Specimen by NAA with probe detection |
96752-1 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene mutation [Presence] in Specimen by Molecular genetics method |
96751-3 | http://loinc.org | SARS-CoV-2 (COVID-19) S gene mutation detected [Identifier] in Specimen by Molecular genetics method |
99597-7 | http://loinc.org | SARS-CoV-2 (COVID-19) S protein IgG Ab [Presence] in Serum or Plasma by Immunoassay |
96603-6 | http://loinc.org | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT |
98732-1 | http://loinc.org | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Titer] in Serum or Plasma by Immunoassay |
98734-7 | http://loinc.org | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Units/volume] in Serum or Plasma by Immunoassay |
96894-1 | http://loinc.org | SARS-CoV-2 (COVID-19) sequencing and identification panel - Specimen by Molecular genetics method |
95970-0 | http://loinc.org | SARS-CoV-2 (COVID-19) specific TCRB gene rearrangements [Presence] in Blood by Sequencing |
100156-9 | http://loinc.org | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by NAA with probe detection |
96741-4 | http://loinc.org | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing |
96755-4 | http://loinc.org | SARS-CoV-2 (COVID-19) variant interpretation in Specimen Narrative |
94764-8 | http://loinc.org | SARS-CoV-2 (COVID-19) whole genome [Nucleotide sequence] in Isolate or Specimen by Sequencing |
99772-6 | http://loinc.org | SARS-CoV-2 stimulated gamma interferon [Interpretation] in Blood Qualitative |
95971-8 | http://loinc.org | SARS-CoV-2 stimulated gamma interferon [Presence] in Blood |
95974-2 | http://loinc.org | SARS-CoV-2 stimulated gamma interferon panel - Blood |
95972-6 | http://loinc.org | SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood |
95973-4 | http://loinc.org | SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] in Blood |
94509-7 | http://loinc.org | SARS-related coronavirus E gene [Cycle Threshold #] in Specimen by NAA with probe detection |
96121-9 | http://loinc.org | SARS-related coronavirus E gene [Presence] in Lower respiratory specimen by NAA with probe detection |
94758-0 | http://loinc.org | SARS-related coronavirus E gene [Presence] in Respiratory system specimen by NAA with probe detection |
95823-1 | http://loinc.org | SARS-related coronavirus E gene [Presence] in Saliva (oral fluid) by NAA with probe detection |
94765-5 | http://loinc.org | SARS-related coronavirus E gene [Presence] in Serum or Plasma by NAA with probe detection |
94315-9 | http://loinc.org | SARS-related coronavirus E gene [Presence] in Specimen by NAA with probe detection |
96122-7 | http://loinc.org | SARS-related coronavirus E gene [Presence] in Upper respiratory specimen by NAA with probe detection |
94313-4 | http://loinc.org | SARS-related coronavirus N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 |
94310-0 | http://loinc.org | SARS-related coronavirus N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 |
94502-2 | http://loinc.org | SARS-related coronavirus RNA [Presence] in Respiratory system specimen by NAA with probe detection |
94647-5 | http://loinc.org | SARS-related coronavirus RNA [Presence] in Specimen by NAA with probe detection |
94532-9 | http://loinc.org | SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory system specimen by NAA with probe detection |
100342-5 | http://loinc.org | Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry |
100972-9 | http://loinc.org | Influenza virus A and Influenza virus B and SARS coronavirus 2 RNA panel - Nose by NAA with non-probe detection |
87637 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
87631 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets |
87632 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets |
87633 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets |
87635 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique |
87636 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
0241U | http://www.ama-assn.org/go/cpt | Respiratory infectious agent detection by RNA for severe acute respiratory syndrome coronavirus 2 (COVID 19), influenza A, influenza B, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected |
86328 | http://www.ama-assn.org/go/cpt | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
86408 | http://www.ama-assn.org/go/cpt | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen |
86409 | http://www.ama-assn.org/go/cpt | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer |
86413 | http://www.ama-assn.org/go/cpt | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative |
87811 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
0224U | http://www.ama-assn.org/go/cpt | Measurement of antibody to severe acute respiratory syndrome coronavirus 2 (COVID-19) |
0226U | http://www.ama-assn.org/go/cpt | Surrogate viral neutralization test (sVNT) for detection of antibodies to severe acute respiratory syndrome coronavirus 2 (Covid-19) by |
0202U | http://www.ama-assn.org/go/cpt | Test for detection of respiratory disease-causing organisms from back of nose and throat (nasopharynx) specimen, 22 target organisms including severe acute respiratory syndrome coronavirus 2 |
0223U | http://www.ama-assn.org/go/cpt | Test for detection of respiratory disease-causing organisms from back of nose and throat (nasopharynx) specimen, 22 target organisms including severe acute respiratory syndrome coronavirus 2 |
0225U | http://www.ama-assn.org/go/cpt | Test for detection of respiratory disease-causing organisms, 21 target organisms including severe acute respiratory syndrome coronavirus 2 (COVID-19) |
87913 | http://www.ama-assn.org/go/cpt | Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s) |
0240U | http://www.ama-assn.org/go/cpt | Respiratory infectious agent detection by RNA for severe acute respiratory syndrome coronavirus 2 (COVID-19), influenza A, and influenza B) in upper respiratory specimen, each reported as detected or not detected |
87426 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) |
87428 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B |
86318 | http://www.ama-assn.org/go/cpt | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); |
87252 | http://www.ama-assn.org/go/cpt | Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect |
Explanation of the columns that may appear on this page:
Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
Code | The code (used as the code in the resource instance) |
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
Definition | An explanation of the meaning of the concept |
Comments | Additional notes about how to use the code |